Andere talen Nurix Therapeutics, Inc.

Aandelen

NRIX

US67080M1036

Geschatte realtime Cboe BZX Andere beurzen 21:39:32 07-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
14,3 ^USD	+8,21%		+18,51%	+38,03%

12/04	Sectorupdate: Aandelen in de gezondheidszorg stabiel voor de beurs op vrijdag	MT
12/04	Sectorupdate: Gezondheidszorg	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference	13:13
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	17/04
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	15/04
Sector Update: Health Care Stocks Steady Pre-Bell Friday	12/04
Sector Update: Health Care	12/04
North American Morning Briefing : Big Banks Kick off Earnings Season	12/04
Nurix Therapeutics Prices Upsized Stock Offering at $15 a Share	12/04
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering	12/04
Nurix Therapeutics Launching Public Offering -- Shares Fall After-Hours	11/04
Nurix Therapeutics Announces Proposed Public Offering	11/04
Nurix Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10/04
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update	10/04
Earnings Flash (NRIX) NURIX THERAPEUTICS Reports Q1 Revenue $16.6M	10/04
North American Morning Briefing : Traders Await -2-	10/04
Nurix Therapeutics Shares Climb 19% on Extended Sanofi Collaboration	09/04
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	09/04
Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies	09/04
Nurix Therapeutics Extends Collaboration With Sanofi, Aims to Nominate Clinical Candidate	09/04
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	09/04
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6	09/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nurix Therapeutics, Inc.

Aandelen

NRIX

US67080M1036

Andere talen

Filters